Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in PFS and OS in Patients with Platinum-Resistant Ovarian Cancer October 27, 2026
VS-7375 Demonstrates 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed) October 20, 2026
Data from FURTHER Ph 1b (FURMO-002) of firmonertinib in 1L EGFR PACC-mutant NSCLC published in Cancer Cell October 20, 2026
Positive Ph 2 Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic CRC Announced October 20, 2026
Efficacy Data presented from Ph 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy October 20, 2026
Ph 3 Data Shows 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® + BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors October 20, 2026
Positive Topline Results from Interim Analysis of Ph 3 ACTION-1 for RYZ101 Announced in Patients with GEP-NETs October 14, 2026
ZENBEXUS (iberdomide) + ZDd Demonstrates Superior PFS vs. SOC in RRMM patients in Ph 3 EXCALIBER-RRMM Study October 14, 2026
Epcoritamab + R-CHOP Demonstrates Statistically Significant PFS Improvement in Patients with 1L DLBCL October 14, 2026
Carotuximab + Apalutamide Improves PFS in Interim Ph 2 Prostate Cancer trial of ENV-105 October 14, 2026
Statistically Significant Final Three-Year OS Benefit observed for Herlystic-Treated Patients in Ph 2b Pulmonary Metastatic Osteosarcoma Trial October 14, 2026
FAILED TRIAL: AHEAD-MERIT Ph 2/3 trial did not meet first dual primary endpoint of PFS for BNT113 + pembrolizumab vs pembrolizumab in HPV16+ HNSCC patients October 14, 2026
FAILED TRIAL: FURVENT Ph 3 trial of firmonertinib monotherapy in NSCLC patients with EGFR exon 20 insertion mutations did not meet primary PFS endpoint by BICR October 14, 2026
FAILED TRIAL: Ph 2b SURVIVE Trial of SurVaxM in Newly Diagnosed GBM didn’t meet primary endpoint of OS improvement October 14, 2026
Giredestrant combination significantly improved PFS in ER-positive advanced breast cancer in Ph 3 evERA; data published in The NEJM October 6, 2026
Epcoritamab + R-CHOP combo Demonstrates Significant PFS Improvement versus R-CHOP in 1L DLBCL Patients October 6, 2026
Results from VIRAGE Ph 2b Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine October 6, 2026
Positive topline results from Ph 3 AZTOUND trial of oral azacitidine and cedazuridine (ASTX030) in MDS and CMML patients announced October 6, 2026
RD140 achieved ~89% ORR & MRD negativity rate in heavily pretreated, high-risk RRMM or plasma cell leukemia patients October 6, 2026
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC) October 6, 2026
Rinatabart Sesutecan (Rina-S®) Ph 2 RAINFOL™-01 Results Demonstrate Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer October 6, 2026
Results Announced for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Ph 3 EXCALIBER-RRMM Trial in RRMM Patients October 1, 2026
Nature Medicine Publication of ASPEN-06 Ph 2 Data Demonstrates Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer October 1, 2026
